<DOC>
	<DOCNO>NCT02416427</DOCNO>
	<brief_summary>This pre-surgical , window-of-opportunity study design investigate whether atorvastatin reduces proliferation marker Ki-67 via modulation Hippo transducer TAZ .</brief_summary>
	<brief_title>Targeting Hippo Transducer TAZ Breast Cancer With Statins</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Inclusion : Signed write informed consent Female age &gt; 18 year &lt; 75 year time enrolment Histologically confirm Breast Cancer ( BC ) independently intrinsic subtype Stage IIIa BC patient candidate elective surgery BC express Ki67 ≥ 15 % TAZ &gt; 10 % diagnostic core biopsy Adequate baseline organ function Negative pregnancy test Exclusion : Previous systemic therapy include chemotherapy , hormone therapy target agent Administration investigational drug prior enrolment History another malignancy , except history completely resect nonmelanoma skin cancer successfully treat cervical situ carcinoma Eastern Cooperative Oncology Group ( ECOG ) performance status ≥2 Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome asymptomatic gallstone ) Serious cardiac illness medical condition include confine : history document congestive heart failure ( CHF ) systolic dysfunction ( LVEF &lt; 50 % ) ; highrisk uncontrolled arrhythmia ( ventricular tachycardia , highgrade AVblock , supraventricular arrhythmia adequately control ) ; angina pectoris require antianginal medication ; clinically significant valvular heart disease ; evidence transmural infarction ECG ; poorly control hypertension ( e.g . systolic &gt; 180mm Hg diastolic &gt; 100mm Hg ) Have concurrent disease condition may interfere study participation , serious medical disorder would interfere subject 's safety ( example , active uncontrolled infection psychiatric condition prohibit understanding rendering informed consent ) Current recent therapy statins hypercholesterolemia lipidlowering drug Current recent therapy glucoselowering drug diabetes Current recent therapy strong CYP3A4 inhibitor ( e.g. , clarithromycin , HIV protease inhibitor , itraconazole ) give potential interaction atorvastatin Current recent therapy gemfibrozil fibrates give potential interaction atorvastatin . Patients pregnant breastfeeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Atorvastatin</keyword>
	<keyword>TAZ</keyword>
	<keyword>Hippo pathway</keyword>
	<keyword>ki67</keyword>
</DOC>